ZyVersa Therapeutics Targets $70 Billion Market in Innovative Biotech Breakthrough 🚀

Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. was recently a guest on Benzinga’s All-Access.<br /><br />ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop transformative drugs for underserved patients with renal and inflammatory diseases. The company is currently advancing a therapeutic pipeline with multiple programs built around its two proprietary technologies – VAR 200 and IC 100.<br /><br />The technologies could represent a leap forward in the treatment of several diseases.